2020
Androgenicity and fertility treatment in women with unexplained infertility
Wang ET, Diamond MP, Alvero R, Casson P, Christman GM, Coutifaris C, Hansen KR, Sun F, Legro RS, Robinson RD, Usadi RS, Pisarska MD, Santoro NF, Zhang H, Network I. Androgenicity and fertility treatment in women with unexplained infertility. Fertility And Sterility 2020, 113: 636-641. PMID: 32192596, PMCID: PMC7088440, DOI: 10.1016/j.fertnstert.2019.10.034.Peer-Reviewed Original ResearchConceptsLive birth rateBody mass indexUnexplained infertilityClinical pregnancyMass indexPregnancy lossClinical markersLive birthsAndrogenic activityFree androgen index valuesHigher body mass indexMultivariable logistic regression modelMultiple Intrauterine GestationsNormal uterine cavityHigh waist circumferenceOvarian stimulation treatmentPatent fallopian tubesBirth rateLogistic regression modelsAndrogen markersSerum TTOvarian stimulationRegular mensesInfertility populationIntrauterine gestation
2019
Lower prevalence of non–cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility
Huang H, Kuang H, Sun F, Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson PR, Christman GM, Hansen KR, Santoro N, Eisenberg E, Zhang H, Network E. Lower prevalence of non–cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility. Fertility And Sterility 2019, 111: 1011-1019.e1. PMID: 30926125, PMCID: PMC6487215, DOI: 10.1016/j.fertnstert.2019.01.020.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeUnexplained infertilityUterine fibroidsLow prevalenceOvary syndromeDifferent body mass index (BMI) groupsBody mass index groupsHigher body mass indexHigher total testosteroneNormal uterine cavityAssessment-insulin resistanceBody mass indexRandomized clinical trialsCurrent alcohol usersPrevalence of womenTotal testosteroneCurrent smokersInfertile womenLarge fibroidsMass indexInfertile patientsInsulin resistanceUterine cavityClinical trialsLower percentage
2017
Association of uterine fibroids and pregnancy outcomes after ovarian stimulation–intrauterine insemination for unexplained infertility
Styer AK, Jin S, Liu D, Wang B, Polotsky AJ, Christianson MS, Vitek W, Engmann L, Hansen K, Wild R, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Christy A, Diamond MP, Eisenberg E, Zhang H, Santoro N, Network I. Association of uterine fibroids and pregnancy outcomes after ovarian stimulation–intrauterine insemination for unexplained infertility. Fertility And Sterility 2017, 107: 756-762.e3. PMID: 28089575, PMCID: PMC5472203, DOI: 10.1016/j.fertnstert.2016.12.012.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, SpontaneousAdultBlack or African AmericanDrug Therapy, CombinationFemaleFertilityFertility AgentsHumansInfertilityInsemination, ArtificialLeiomyomaLive BirthOvulationOvulation InductionPregnancyPregnancy RatePregnancy TestsProspective StudiesRisk FactorsTreatment OutcomeUnited StatesUterine NeoplasmsConceptsUnexplained infertilityUterine fibroidsPregnancy outcomesClinical trialsSerum antimüllerian hormone levelsBirth rateNon-African American womenGreater uterine volumeMultiple Intrauterine GestationsNormal uterine cavityClinical pregnancy rateAntimüllerian hormone levelsMulticenter clinical trialAmerican womenAfrican American womenClinical pregnancyIntrauterine gestationUterine volumeConception cyclesUterine cavityPregnancy lossHormone levelsPregnancy rateAntral folliclesMAIN OUTCOME
2015
Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility
Diamond M, Legro R, Coutifaris C, Alvero R, Robinson R, Casson P, Christman G, Ager J, Huang H, Hansen K, Baker V, Usadi R, Seungdamrong A, Bates G, Rosen R, Haisenleder D, Krawetz S, Barnhart K, Trussell J, Ohl D, Jin Y, Santoro N, Eisenberg E, Zhang H. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. Obstetrical & Gynecological Survey 2015, 70: 757-758. DOI: 10.1097/ogx.0000000000000275.Peer-Reviewed Original ResearchOvarian stimulationUnexplained infertilityMultiple gestationsLetrozole groupCongenital anomaliesPregnancy rateLive birthsNormal uterine cavityStandard therapy groupUse of clomipheneOvarian hyperstimulation syndromeFirst-line therapyLive birth ratePatent fallopian tubesPolycystic ovary syndromeMultiple gestation ratesCause of infertilityPlacebo control groupNormal sperm countYears of ageImproved pregnancy ratesFetal heart activityHyperstimulation syndromeMonofollicular developmentNeonatal complications
2014
Letrozole Versus Clomiphene for Infertility in the Polycystic Ovary Syndrome
Legro R, Brzyski R, Diamond M, Coutifaris C, Schlaff W, Casson P, Christman G, Huang H, Yan Q, Alvero R, Haisenleder D, Barnhart K, Bates G, Usadi R, Lucidi S, Baker V, Trussell J, Krawetz S, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H. Letrozole Versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. Obstetrical & Gynecological Survey 2014, 69: 599-601. DOI: 10.1097/01.ogx.0000456355.64379.77.Peer-Reviewed Original ResearchPolycystic ovary syndromeAdverse effect profileMultiple pregnancy rateEffect profileFertility agentsAromatase inhibitorsLive birthsHigher multiple pregnancy rateLower multiple pregnancy rateSelective estrogen receptor modulatorsMale partnersNormal uterine cavityPatent fallopian tubesPrimary study outcomeCumulative live birthReproductive-age womenGood safety profileEstrogen receptor modulatorsClomiphene groupLetrozole groupClomiphene citrateRotterdam criteriaHot flushesOvary syndromeInfertile womenLetrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome
Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. New England Journal Of Medicine 2014, 371: 119-129. PMID: 25006718, PMCID: PMC4175743, DOI: 10.1056/nejmoa1313517.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeOvary syndromeCongenital anomaliesLive birthsHigh incidenceOvulation rateSignificant between-group differencesCumulative ovulation rateNormal uterine cavityOverall congenital anomaliesBetter pregnancy outcomesPatent fallopian tubesCumulative live birthMajor congenital anomaliesBetween-group differencesYears of ageClomiphene groupLetrozole groupRotterdam criteriaAdverse eventsHot flushesPregnancy outcomesInfertile womenMulticenter trialPrimary outcome